Overview

Welcome to Stayble Therapeutics AB´s IR pages

Stayble Therapeutics is a clinical stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. STA363 is intended for patients not improving after treatment with analgesics and physiotherapy.

LATEST PRESS RELEASES

22 February 2021 Regulatory

Stayble Therapeutic’s rights issue oversubscribed

The subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) rights issue ended on 17 February 2021. The rights issue was subscribed to a total of approximately 268 perc...

03 February 2021 Regulatory

Information about the trading in subscription rights and BTA

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby informs that the first day of trading in subscription rights and paid subscribed share ("BTA"), in connection with the Company's ong...

FINANCIAL CALENDAR

Interim report Q4 2020
31March2021